SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* COPPLE BRIAN W (Last) (First) (Middle) THREE RAVINIA DRIVE (Street) ATLANTA GA 30346 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ECLIPSYS CORP [ ECLP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) General Counsel
	3. Date of Earliest Transaction (Month/Day/Year) 08/24/2010
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/24/2010		D(1)		28,878(1)	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.6	08/24/2010		D(2)			45,000	(2)	(2)	Common Stock	45,000	$0.00	0	D
Stock Option	$22.07	08/24/2010		D(3)			28,000	(3)	(3)	Common Stock	28,000	$0.00	0	D
Stock Option	$7.97	08/24/2010		D(4)			50,000	(4)	(4)	Common Stock	50,000	$0.00	0	D
Stock Option	$7.97	08/24/2010		D(5)			45,000	(5)	(5)	Common Stock	45,000	$0.00	0	D

Explanation of Responses:

1. As the transaction was fully described in the joint proxy statement dated July 14, 2010, as filed with the SEC, each Issuer share was converted into 1.2 shares of common stock of Allscripts Healthcare Solutions, Inc. pursuant to a merger of Issuer with a wholly-owned subsidiary of Allscripts. Shares that were converted included 8,249 shares of Issuer unvested restricted stock that will be subject to the same terms as specified in the original grant notice and Reporting Person's employment documents. Disposition by Reporting Person was approved by Issuer board of directors.

2. In connection with the merger described above, each Issuer option was converted into an option to purchase Allscripts common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Reporting Person's options were fully vested. Disposition by Reporting Person was approved by Issuer board of directors.

3. In connection with the merger described above, each Issuer option was converted into an option to purchase Allscripts common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 16,917 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents and Reporting Person's employment documents. Disposition by Reporting Person was approved by Issuer board of directors.

4. In connection with the merger described above, each Issuer option was converted into an option to purchase Allscripts common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 17,708 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents and Reporting Person's employment documents. Disposition by Reporting Person was approved by Issuer board of directors.

5. In connection with the merger described above, each Issuer option was converted into an option to purchase Allscripts common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 15,938 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents and Reporting Person's employment documents. Disposition by Reporting Person was approved by Issuer board of directors.

Remarks:

	Brian W. Copple	08/26/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.